JP2003522189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522189A5 JP2003522189A5 JP2001558051A JP2001558051A JP2003522189A5 JP 2003522189 A5 JP2003522189 A5 JP 2003522189A5 JP 2001558051 A JP2001558051 A JP 2001558051A JP 2001558051 A JP2001558051 A JP 2001558051A JP 2003522189 A5 JP2003522189 A5 JP 2003522189A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- thio
- methyl
- product
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 51
- 150000001875 compounds Chemical class 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- 239000000047 product Substances 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 239000000243 solution Substances 0.000 description 28
- 239000007787 solid Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 206010039083 rhinitis Diseases 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- -1 2,3-difluorophenyl Chemical group 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 3
- 0 CCOC(Nc([n]1)nc(c(*)n2)c1nc2S)=O Chemical compound CCOC(Nc([n]1)nc(c(*)n2)c1nc2S)=O 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- ADEMRMNQYDVKRV-SECBINFHSA-N (2r)-2-[[8-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]butan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)CC)=NC=1SCC1=CC=CC(F)=C1F ADEMRMNQYDVKRV-SECBINFHSA-N 0.000 description 2
- VNGOAGLZSGVQHX-SSDOTTSWSA-N (2r)-2-[[8-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F VNGOAGLZSGVQHX-SSDOTTSWSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- FTBSGSZZESQDBM-UHFFFAOYSA-N 1-(bromomethyl)-2,3-difluorobenzene Chemical compound FC1=CC=CC(CBr)=C1F FTBSGSZZESQDBM-UHFFFAOYSA-N 0.000 description 2
- MCBMLPDEXRAKDO-MRVPVSSYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C=2NC(=O)CC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F MCBMLPDEXRAKDO-MRVPVSSYSA-N 0.000 description 2
- JKVINFJVZJHNLK-UHFFFAOYSA-N 2-[[8-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]-2-methylpropan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(NC(C)(CO)C)=NC=1SCC1=CC=CC(F)=C1F JKVINFJVZJHNLK-UHFFFAOYSA-N 0.000 description 2
- PYMFWZQOVMSEJK-UHFFFAOYSA-N 2-[[8-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]-2-methylpropane-1,3-diol Chemical compound N=1C=2NC(N)=NC=2C(NC(CO)(CO)C)=NC=1SCC1=CC=CC(F)=C1F PYMFWZQOVMSEJK-UHFFFAOYSA-N 0.000 description 2
- KSTLGFMLCSREDG-UHFFFAOYSA-N 2-[[8-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]propane-1,3-diol Chemical compound N1=C2NC(N)=NC2=C(NC(CO)CO)N=C1SCC1=CC=CC(F)=C1F KSTLGFMLCSREDG-UHFFFAOYSA-N 0.000 description 2
- RURRPCNSHIMRGD-SECBINFHSA-N 2-benzylsulfanyl-6-[[(2r)-1-hydroxypropan-2-yl]amino]-7,9-dihydropurin-8-one Chemical compound N=1C=2NC(=O)NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1 RURRPCNSHIMRGD-SECBINFHSA-N 0.000 description 2
- UUQYSXBFJGFLKV-UHFFFAOYSA-N 4-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C=2NC(=O)CC=2C(N)=NC=1SCC1=CC=CC(F)=C1F UUQYSXBFJGFLKV-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- KJOWSAVFSCSBMZ-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methylazanium;chloride Chemical compound Cl.COC1=CC=C(CN)C(OC)=C1 KJOWSAVFSCSBMZ-UHFFFAOYSA-N 0.000 description 1
- HNISIXROLNYCDM-SECBINFHSA-N (2r)-2-[(8-amino-2-benzylsulfanyl-7h-purin-6-yl)amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1 HNISIXROLNYCDM-SECBINFHSA-N 0.000 description 1
- GDTREHIOQWBWJN-SECBINFHSA-N (2r)-2-[[6-amino-2-[(2-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]amino]propan-1-ol Chemical compound OC[C@@H](C)NC1=CC(N)=NC(SCC=2C(=CC=CC=2)F)=N1 GDTREHIOQWBWJN-SECBINFHSA-N 0.000 description 1
- MKLKVMAYCTWMMU-MRVPVSSYSA-N (2r)-2-[[8-amino-2-(1,3-benzodioxol-4-ylmethylsulfanyl)-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC2=C1OCO2 MKLKVMAYCTWMMU-MRVPVSSYSA-N 0.000 description 1
- QVHDGKCBQUZUBN-MRVPVSSYSA-N (2r)-2-[[8-amino-2-[(2-bromophenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1Br QVHDGKCBQUZUBN-MRVPVSSYSA-N 0.000 description 1
- PKZKDRUQEOVESZ-MRVPVSSYSA-N (2r)-2-[[8-amino-2-[(2-fluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1F PKZKDRUQEOVESZ-MRVPVSSYSA-N 0.000 description 1
- NYPVTAVIUQXVBD-SNVBAGLBSA-N (2r)-2-[[8-amino-2-[(2-methylphenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1C NYPVTAVIUQXVBD-SNVBAGLBSA-N 0.000 description 1
- ROEMIMZCSNFQTP-SSDOTTSWSA-N (2r)-2-[[8-amino-2-[(3-chloro-2-fluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(Cl)=C1F ROEMIMZCSNFQTP-SSDOTTSWSA-N 0.000 description 1
- YWPYWSARFFOWGB-MRVPVSSYSA-N (2r)-2-[[8-amino-2-[(3-chloro-4-methoxyphenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound C1=C(Cl)C(OC)=CC=C1CSC1=NC(N[C@H](C)CO)=C(N=C(N)N2)C2=N1 YWPYWSARFFOWGB-MRVPVSSYSA-N 0.000 description 1
- FYJXTHIJKZOBDD-MRVPVSSYSA-N (2r)-2-[[8-amino-2-[(3-chlorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(Cl)=C1 FYJXTHIJKZOBDD-MRVPVSSYSA-N 0.000 description 1
- ANEZWBQXYCKHBF-SECBINFHSA-N (2r)-2-[[8-amino-2-[(3-methoxyphenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound COC1=CC=CC(CSC=2N=C3NC(N)=NC3=C(N[C@H](C)CO)N=2)=C1 ANEZWBQXYCKHBF-SECBINFHSA-N 0.000 description 1
- TUZBVXBBJUMRKH-SNVBAGLBSA-N (2r)-2-[[8-amino-2-[(3-methylphenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(C)=C1 TUZBVXBBJUMRKH-SNVBAGLBSA-N 0.000 description 1
- UHMAUIOYRZTETM-SNVBAGLBSA-N (2r)-2-[[8-amino-2-[(4-methylphenyl)methylsulfanyl]-7h-purin-6-yl]amino]propan-1-ol Chemical compound N=1C=2NC(N)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=C(C)C=C1 UHMAUIOYRZTETM-SNVBAGLBSA-N 0.000 description 1
- JCBPETKZIGVZRE-SCSAIBSYSA-N (2r)-2-aminobutan-1-ol Chemical compound CC[C@@H](N)CO JCBPETKZIGVZRE-SCSAIBSYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- UUSHWADNFWAUQP-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-5-nitrosopyrimidine-4,6-diamine Chemical compound NC1=C(N=O)C(N)=NC(SCC=2C(=C(F)C=CC=2)F)=N1 UUSHWADNFWAUQP-UHFFFAOYSA-N 0.000 description 1
- SYZOJSBWVZKNNP-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]pyrimidine-4,5,6-triamine Chemical compound NC1=C(N)C(N)=NC(SCC=2C(=C(F)C=CC=2)F)=N1 SYZOJSBWVZKNNP-UHFFFAOYSA-N 0.000 description 1
- QDUYLZMCFOXYAB-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-hydroxy-6-oxo-1h-pyrimidin-5-yl]acetic acid Chemical compound N1=C(O)C(CC(=O)O)=C(O)N=C1SCC1=CC=CC(F)=C1F QDUYLZMCFOXYAB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JWTXBTQLUWRAGK-UHFFFAOYSA-N 2-[4-chloro-2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2,4-dimethoxyphenyl)methylamino]pyrimidin-5-yl]acetic acid Chemical compound COC1=CC(OC)=CC=C1CNC1=NC(SCC=2C(=C(F)C=CC=2)F)=NC(Cl)=C1CC(O)=O JWTXBTQLUWRAGK-UHFFFAOYSA-N 0.000 description 1
- VOUCOPWIMWCBPG-UHFFFAOYSA-N 2-[[8-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-6-yl]amino]ethanol Chemical compound N1=C2NC(N)=NC2=C(NCCO)N=C1SCC1=CC=CC(F)=C1F VOUCOPWIMWCBPG-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- FONJIJWCXJZLND-UHFFFAOYSA-N 2-benzylsulfanyl-4,6-dichloro-5-nitropyrimidine Chemical compound N1=C(Cl)C([N+](=O)[O-])=C(Cl)N=C1SCC1=CC=CC=C1 FONJIJWCXJZLND-UHFFFAOYSA-N 0.000 description 1
- JZLXPDXFQHWKND-UHFFFAOYSA-N 2-benzylsulfanyl-4-hydroxy-5-nitro-1h-pyrimidin-6-one Chemical compound OC1=C([N+]([O-])=O)C(O)=NC(SCC=2C=CC=CC=2)=N1 JZLXPDXFQHWKND-UHFFFAOYSA-N 0.000 description 1
- DRHYOMFDXKXRRS-UHFFFAOYSA-N 2-benzylsulfanyl-6-chloro-7,9-dihydropurin-8-one Chemical compound N=1C=2NC(=O)NC=2C(Cl)=NC=1SCC1=CC=CC=C1 DRHYOMFDXKXRRS-UHFFFAOYSA-N 0.000 description 1
- KXTKJBKITLZAAP-UHFFFAOYSA-N 2-benzylsulfanyl-6-chloropyrimidine-4,5-diamine Chemical compound ClC1=C(N)C(N)=NC(SCC=2C=CC=CC=2)=N1 KXTKJBKITLZAAP-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- NTHGIYFSMNNHSC-UHFFFAOYSA-N 3-methylbutyl nitrate Chemical compound CC(C)CCO[N+]([O-])=O NTHGIYFSMNNHSC-UHFFFAOYSA-N 0.000 description 1
- BYIVZSPGIKQEKK-UHFFFAOYSA-N 4-chloro-2-[(2,3-difluorophenyl)methylsulfanyl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound FC1=CC=CC(CSC=2N=C(Cl)C=3CC(=O)NC=3N=2)=C1F BYIVZSPGIKQEKK-UHFFFAOYSA-N 0.000 description 1
- GOBSBYDYHYYLLA-UHFFFAOYSA-N 6-chloro-2-[(2-fluorophenyl)methylsulfanyl]pyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(SCC=2C(=CC=CC=2)F)=N1 GOBSBYDYHYYLLA-UHFFFAOYSA-N 0.000 description 1
- XLZPAEFOPLTJNT-UHFFFAOYSA-N 6-chloro-2-[(3-chlorophenyl)methylsulfanyl]pyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(SCC=2C=C(Cl)C=CC=2)=N1 XLZPAEFOPLTJNT-UHFFFAOYSA-N 0.000 description 1
- CSQQNVIOXRYCJU-GSVOUGTGSA-N 8-amino-6-[[(2r)-1-hydroxypropan-2-yl]amino]-3,7-dihydropurine-2-thione Chemical compound N1C(S)=NC2=NC(N)=NC2=C1N[C@@H](CO)C CSQQNVIOXRYCJU-GSVOUGTGSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- KPBKSMLOLLLVGK-MRVPVSSYSA-N [2-[(2-fluorophenyl)methylsulfanyl]-6-[[(2r)-1-hydroxypropan-2-yl]amino]-7h-purin-8-yl]carbamic acid Chemical compound N=1C=2NC(NC(O)=O)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1F KPBKSMLOLLLVGK-MRVPVSSYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 1
- AYESBPNRKZGSGP-UHFFFAOYSA-N ethyl n-[6-bromo-2-[(2,3-difluorophenyl)methylsulfanyl]-7h-purin-8-yl]carbamate Chemical compound N1=C2NC(NC(=O)OCC)=NC2=C(Br)N=C1SCC1=CC=CC(F)=C1F AYESBPNRKZGSGP-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0003019A GB2359078A (en) | 2000-02-11 | 2000-02-11 | Pharmaceutically active pyrimidine derivatives |
| GB0003019.7 | 2000-02-11 | ||
| PCT/SE2001/000245 WO2001058902A1 (en) | 2000-02-11 | 2001-02-07 | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003522189A JP2003522189A (ja) | 2003-07-22 |
| JP2003522189A5 true JP2003522189A5 (https=) | 2008-03-27 |
Family
ID=9885284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001558051A Pending JP2003522189A (ja) | 2000-02-11 | 2001-02-07 | ケモカインレセプター活性のモジュレーターとしてのピリミジン化合物およびそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6958344B2 (https=) |
| EP (1) | EP1265899A1 (https=) |
| JP (1) | JP2003522189A (https=) |
| AU (1) | AU2001230704A1 (https=) |
| GB (1) | GB2359078A (https=) |
| WO (1) | WO2001058902A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| DE60101372T2 (de) * | 2000-02-11 | 2004-10-14 | Astrazeneca Ab | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| SE0003828D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| EP2399903A1 (en) * | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| US7482355B2 (en) | 2002-08-24 | 2009-01-27 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
| GB0221828D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0328243D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| GB0401269D0 (en) * | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| ES2294400T3 (es) * | 2004-06-29 | 2008-04-01 | Grunenthal Gmbh | Nuevos analogos de notrobenciltioinosina. |
| KR101280095B1 (ko) | 2004-08-28 | 2013-09-09 | 아스트라제네카 아베 | 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체 |
| WO2009042139A1 (en) * | 2007-09-25 | 2009-04-02 | Actimis Pharmaceuticals, Inc. | 2-s-benzyl substituted pyrimidines as crth2 antagonists |
| ATE547407T1 (de) | 2007-09-25 | 2012-03-15 | Actimis Pharmaceuticals Inc | Alkylthiopyrimidine als crth2-antagonisten |
| AU2009322836B2 (en) * | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| MX2013002895A (es) * | 2010-09-14 | 2013-06-05 | Inst Biochemii I Biofizyki Pan | Compuestos como moduladores de una proteina cftr mutante y su uso para tratar enfermedades asociadas con las deficiencias de la proteina cftr. |
| CN109020882A (zh) * | 2018-08-09 | 2018-12-18 | 杭州华东医药集团浙江华义制药有限公司 | 3,5-二氯-2-氰基吡啶的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318900A (en) | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| DE2331223C2 (de) | 1972-06-19 | 1984-11-22 | Kohjin Co., Ltd., Tokio / Tokyo | S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten |
| JPS5188994A (en) * | 1975-02-04 | 1976-08-04 | Shinkijichikan 88 aminoadeninjudotainoseizoho | |
| EG12406A (en) | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
| FR2421899A1 (fr) | 1978-01-16 | 1979-11-02 | Roussel Uclaf | Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits |
| US4410528A (en) | 1980-05-16 | 1983-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Hypotensive piperidine derivatives |
| CA1338012C (en) | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
| FR2659656B1 (fr) | 1990-03-15 | 1994-09-09 | Sanofi Sa | Derives de pyrimidinedione-2,4 et medicaments les contenant. |
| DE4119767A1 (de) | 1991-06-15 | 1992-12-17 | Dresden Arzneimittel | Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten |
| US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| DE69628804T2 (de) * | 1995-12-08 | 2003-12-18 | Pfizer Inc., New York | Substitutierte heterozyclische Derivate als CRF Antagonisten |
| WO1997040035A1 (en) | 1996-04-19 | 1997-10-30 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| IL127566A0 (en) | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| NZ504800A (en) * | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
| EA200000683A1 (ru) | 1998-01-19 | 2000-12-25 | Пфайзер Инк. | Производные ряда 4-(2-кето-1-бензимидазолинил)пиперидина в качестве агонистов orl1-рецептора |
| CN1166665C (zh) | 1998-03-19 | 2004-09-15 | 日本农药株式会社 | 芳基哌啶衍生物及其用途 |
| WO1999051608A1 (en) * | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
| SE9802729D0 (sv) * | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| ES2229803T3 (es) | 1998-12-28 | 2005-04-16 | 4 Aza Bioscience Nv | Efectos inmunosupresivos de derivados de pteridina. |
| CA2361561A1 (en) | 1999-02-02 | 2000-08-10 | K.U. Leuven Research & Development | Immunosurpressive effects of pteridine derivatives |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| AU5600100A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| EP1409487A1 (en) | 1999-09-15 | 2004-04-21 | Warner-Lambert Company Llc | Pteridinones as kinase inhibitors |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
| DE60023100T2 (de) | 2000-01-05 | 2006-07-06 | Pfizer Inc. | Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten |
| DE60101372T2 (de) * | 2000-02-11 | 2004-10-14 | Astrazeneca Ab | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359079A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) * | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| SE0102716D0 (sv) | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
-
2000
- 2000-02-11 GB GB0003019A patent/GB2359078A/en not_active Withdrawn
-
2001
- 2001-02-07 JP JP2001558051A patent/JP2003522189A/ja active Pending
- 2001-02-07 EP EP01902950A patent/EP1265899A1/en not_active Withdrawn
- 2001-02-07 US US10/203,584 patent/US6958344B2/en not_active Expired - Fee Related
- 2001-02-07 WO PCT/SE2001/000245 patent/WO2001058902A1/en not_active Ceased
- 2001-02-07 AU AU2001230704A patent/AU2001230704A1/en not_active Abandoned
-
2005
- 2005-01-14 US US11/036,682 patent/US20050234077A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003522189A5 (https=) | ||
| KR100795758B1 (ko) | 건선 치료용 프테리딘 화합물 | |
| KR100765051B1 (ko) | 신규 티아졸로(4,5-ｄ)피리미딘 화합물 | |
| US6806273B1 (en) | Compounds | |
| ES2276836T3 (es) | 7-amino-2-alquiltiopteridin-4-il-aminas para el tratamiento de enfermedades relacionadas con las quimioquinas. | |
| IL150952A (en) | Preparation of dosage forms of clear aqueous solution with bile acids | |
| JP2003522189A (ja) | ケモカインレセプター活性のモジュレーターとしてのピリミジン化合物およびそれらの使用 | |
| JP2003522191A (ja) | ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用 | |
| SA06270072B1 (ar) | مشتقات جديدة من 7- امينو -[ 1، 3] ثيازولو [ 4، 5-d] بيريميدين بها استبدال في الموضع 5 | |
| ES2289124T3 (es) | Derivados de pteridinona como moduladores de la actividad del receptor de quimioquinas. | |
| JP2003522192A5 (https=) | ||
| JP2004525972A (ja) | チアゾロピリミジンおよびそのケモカインレセプター活性モジュレーターとしての使用 | |
| JP2003522192A (ja) | ケモカインレセプター活性のモジュレーターとしてのチアゾロピリミジンおよびそれらの使用 | |
| Senga et al. | Synthesis and enzymic activity of various substituted pyrazolo [1, 5-a]-1, 3, 5-triazines as adenosine cyclic 3', 5'-phosphate phosphodiesterase inhibitors |